Stelara Related Published Studies
Well-designed clinical trials related to Stelara (Ustekinumab)
Update on ustekinumab for the treatment of Crohn's disease. [2014]
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe
plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS). [2013]
An update on the long-term safety experience of ustekinumab: results from the
psoriasis clinical development program with up to four years of follow-up. [2012]
Long-term safety experience of ustekinumab in patients with moderate to severe
psoriasis (Part II of II): results from analyses of infections and malignancy
from pooled phase II and III clinical trials. [2012]
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe
plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. [2012]
Long-term safety experience of ustekinumab in patients with moderate-to-severe
psoriasis (Part I of II): results from analyses of general safety parameters from
pooled Phase 2 and 3 clinical trials. [2012]
Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. [2011.11.30]
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: Long-term results from a phase 2/3 clinical trial. [2011.09.29]
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). [2011.09]
Bounded outcome score modeling: application to treating psoriasis with ustekinumab. [2011.08]
Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. [2011.07]
Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. [2011.04]
Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis. [2011.04]
The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. [2011.01]
Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab
and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian
perspective. [2011]
Efficacy and safety of ustekinumab for the treatment of moderate-to-severe
psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and
Korean patients (PEARL). [2011]
Informative dropout modeling of longitudinal ordered categorical data and model
validation: application to exposure-response modeling of physician's global
assessment score for ustekinumab in patients with psoriasis. [2011]
Ustekinumab decreases work limitations, improves work productivity, and reduces
work days missed in patients with moderate-to-severe psoriasis: results from
PHOENIX 2. [2011]
Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with
psoriasis: a meta-analysis. [2011]
Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis. [2010.12]
Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial. [2010.10]
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. [2010.09]
Review of the safety and efficacy of ustekinumab. [2010.09]
Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. [2010.07]
Effects of ustekinumab administration on primate/human antigen-recall and humoral immune response functions. [2010.06]
Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. [2010.05]
Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis. [2010.03]
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. [2010.01.14]
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. [2010.01]
Effect of ustekinumab on physical function and health-related quality of life in
patients with psoriatic arthritis: a randomized, placebo-controlled, phase II
trial. [2010]
Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and
systemic parameters. [2010]
Ustekinumab significantly improves symptoms of anxiety, depression, and
skin-related quality of life in patients with moderate-to-severe psoriasis:
Results from a randomized, double-blind, placebo-controlled phase III trial. [2010]
Population-based exposure-efficacy modeling of ustekinumab in patients with
moderate to severe plaque psoriasis. [2010]
Ustekinumab improves health-related quality of life in patients with
moderate-to-severe psoriasis: results from the PHOENIX 1 trial. [2010]
Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. [2009.11]
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. [2009.02.21]
A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. [2008.10]
Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. [2008.09]
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). [2008.05.17]
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). [2008.05.17]
Well-designed clinical trials possibly related to Stelara (Ustekinumab)
Cost-efficacy comparison of biological therapies for patients with moderate to
severe psoriasis in Japan. [2013]
Re-evaluation of the risk for major adverse cardiovascular events in patients
treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a
meta-analysis of randomized controlled trials. [2013]
Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. [2011.09.12]
Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. [2011.09]
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. [2011.08.24]
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis? [2009.03]
Other research related to Stelara (Ustekinumab)
Therapeutic effect and safety of ustekinumab for plaque psoriasis: a
meta-analysis. [2014]
Systematic review and meta-analysis of ustekinumab for moderate to severe
psoriasis. [2014]
Efficacy and safety of mildronate for acute ischemic stroke: a randomized,
double-blind, active-controlled phase II multicenter trial. [2013]
Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in
ustekinumab-treated patients: a randomized intraindividual trial. [2012]
Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: a meta-analysis. [2011.12]
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials. [2011.10.04]
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. [2011.09.17]
311-nm ultraviolet B-enhanced response of psoriatic lesions in ustekinumab-treated patients: a randomized intraindividual trial. [2011.09.12]
Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. [2011.09.10]
Responses to ustekinumab in the anti-TNF agent-naive vs. anti-TNF agent-exposed patients with psoriasis vulgaris. [2011.09]
Impact of ustekinumab on health-related quality of life and sexual difficulties associated with psoriasis: results from two phase III clinical trials. [2011.07]
Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. [2011.06]
New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. [2011.04.01]
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. [2011.03]
Ustekinumab for the treatment of psoriasis. [2011.03]
Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab. [2011.01.10]
Ustekinumab and herpes zoster. [2011]
Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers). [2011]
Ustekinumab for the treatment of psoriasis. [2011]
Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. [2010.10]
Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. [2010.07]
Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials. [2010.04]
The use of ustekinumab in autoimmune disease. [2010.04]
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. [2010.03]
Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. [2010]
Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. [2009.12]
Ustekinumab for the treatment of moderate to severe psoriasis. [2009.10]
Ustekinumab: treatment of adult moderate-to-severe chronic plaque psoriasis. [2009.09]
Ustekinumab: a new option in psoriasis therapy. [2009.06.18]
Ustekinumab. [2009.05]
Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. [2009.02]
Ustekinumab in the therapy of chronic plaque psoriasis. [2009]
Ustekinumab. [2009]
Other possibly related research studies
Comparing biological therapies in psoriasis: implications for clinical practice. [2010.10]
The future of biological therapies. [2010.03]
Treating multiple sclerosis with monoclonal antibodies: a 2010 update. [2010.05]
New drug therapies for multiple sclerosis. [2010.06]
Specific immune intervention with monoclonal antibodies for the treatment of multiple sclerosis. [2010]
The status of biologic therapies in the treatment of moderate to severe psoriasis. [2009.10]
Targeting the interleukin-12/23 cytokine family in the treatment of psoriatic disease. [2008.12]
Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? [2009.09]
Could anti IL12/23 therapy replace anti-TNF biologics? [2009]
Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. [2009.09]
Biologics in the treatment of psoriasis: clinical and economic overview. [2009.09]
[Molecular target drug development for curing multiple sclerosis] [2009.08]
Update on the treatment of peripheral arthritis in psoriatic arthritis. [2009.08]
[Biologic therapies in chronic inflammatory bowel diseases] [2009.05]
Overview of biologic therapy for Crohn's disease. [2009.08]
Biologic survival. [2009.04]
Treatments for psoriasis and the risk of malignancy. [2009.06]
[Biologic therapies in the treatment of psoriasis] [2009.05]
Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents. [2009.03]
New biologics for psoriasis and psoriatic arthritis. [2009.01]
IL-12/IL-23 inhibitors: the advantages and disadvantages of this novel approach for the treatment of psoriasis. [2008.11]
Gateways to clinical trials. [2008.05]
|